推薦產品
品質等級
化驗
≥94% (HPLC)
形狀
(solid or powder)
顏色
, Light Yellow to Dark Yellow
溶解度
DMSO: >25 mg/mL
ethanol: 3 mg/mL (warm)
acetone: 5 mg (plus 0.1 ml)
起源
Merck & Co., Inc., Kenilworth, NJ, U.S.
SMILES 字串
CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C\c3ccc(cc3)S(C)(=O)=O
InChI
1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9+
InChI 密鑰
MVGSNCBCUWPVDA-RQZCQDPDSA-N
應用
Human endothelial cells, HMEC-1 were treated with Sulindac sulfone and the effect on cell survival was studied by MTT assay.
生化／生理作用
Sulindac sulfone is non-steroidal anti-inflammatory drug and an analgesic that has antiproliferative and apoptotic effects. It inhibits the expression and activity of cyclooxygenase-2 in human colon cancer cells1,2 and reduces tumor burden in adenomatous polyposis patients.3
Metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. Inhibits the development and induces regression of premalignant adenomatous polyps.
特點和優勢
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
準備報告
Sulindac sulfone yields clear, light yellow to dark yellow solution in acetone at 50 mg/ml.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
Eyeshields, Gloves, type N95 (US)
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Steven Attia et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 3(9), 1018-1025 (2008-09-02)
Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC). Vinorelbine is safe and effective in older patients with advanced NSCLC. We assessed these agents together as palliative treatment for older patients with advanced NSCLC. Chemotherapy-naive
Ramaswamy Govindan et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 4(2), 220-226 (2009-01-31)
To assess the efficacy and toxicity of carboplatin, etoposide, and exisulind as initial therapy for extensive stage small cell lung cancer. The Cancer and Leukemia Group B conducted a phase II study of carboplatin (area under the curve 6) day
Jun-Yang Liou et al.
Cancer research, 67(7), 3185-3191 (2007-04-06)
To determine the role of 14-3-3 in colorectal cancer apoptosis induced by nonsteroidal anti-inflammatory drugs (NSAIDs), we evaluated the effects of sulindac on 14-3-3epsilon protein expression in colorectal cancer cells. Sulindac sulfide inhibited 14-3-3epsilon proteins in HT-29 and DLD-1 cells
Glen J Weiss et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2(10), 933-938 (2007-10-03)
This multicenter, phase II clinical trial was conducted to evaluate the activity of the combination of docetaxel and exisulind in advanced non-small cell lung cancer (NSCLC) patients who failed a prior platinum-containing regimen. Patients with measurable disease and adequate organ
Nis Giladi et al.
Expert opinion on investigational drugs, 19 Suppl 1, S117-S124 (2010-04-14)
The use of sulindac sulfone (SFN) for colorectal cancer (CRC) therapy is limited due to its toxicity. The present study was carried out to examine whether curcumin, a novel chemopreventive agent, can potentiate the effects of low dosages of SFN
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務